Bio Path Holdings Inc (BPTH)

[SJSTOCKSHARK]

Runnin, I expect the stock PPS will continue to decline once the Russell rebalance occurs. The time is now to raise funds.

The only catalyst for a sustained PPS move upwards is drug approval or a partnership. Neither of these will happen until the triple combination trial shows results. PN admitted it is tough for BPTH to recruit trial patients with the Venetoclax approval. We need enough for 3 to 5 years to complete trials. Selling 1 million shares to the Russell index funds secures the future. A million more shares in the float will have no effect on the company's value if one of their drugs works.